Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Unknown 4Withdrawn 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 22Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 9Nasopharyngeal Carcinoma 5Lung Neoplasms 5Esophageal Squamous Cell Carcinoma 5Small Cell Lung Carcinoma 4Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Lymphoma, Extranodal NK-T-Cell 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma 3Nonsquamous Non-Small Cell Lung Cancer 2Nasopharyngeal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Advanced Biliary Tract Cancer 2Unresectable Locally Advanced Pancreatic Cancer 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Thoracic Malignancies 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Respiratory Tract Diseases 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Rectal Neoplasms 1

Interventions

Exercise 18Drug Therapy 17pembrolizumab 12Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Dexamethasone 9Paclitaxel 8Standard of Care 7Oxaliplatin 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Control Groups 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Neoplasms × sintilimab × Clear all
NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown
15 enrolled
Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT04400851 2020-09-03

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Sun Yat-sen University

Phase 1 Unknown
18 enrolled
Tumor-Agnostic

Neoplasms

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT03874000 2019-03-19

SMART

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
43 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡